Could miglustat be a potential candidate in the treatment of action myoclonus renal failure syndrome?
Acta Neurol Belg
.
2023 Dec;123(6):2441-2444.
doi: 10.1007/s13760-023-02269-z.
Epub 2023 Apr 29.
Authors
Seyda Erdoğan
1
,
Gül Yalçın Çakmaklı
2
,
Bülent Elibol
2
,
Serdar Ceylaner
3
,
M Cenk Akbostancı
4
Affiliations
1
Department of Neurology, School of Medicine, Ankara University, Ibn-I SinaHospital, 06100, Ankara, Turkey. dr_seyda@yahoo.com.
2
Department of Neurology, School of Medicine, Hacettepe University, Ankara, Turkey.
3
Intergen Genetic Diagnosis, Research and Education Center, Ankara, Turkey.
4
Department of Neurology, School of Medicine, Ankara University, Ibn-I SinaHospital, 06100, Ankara, Turkey.
PMID:
37119471
DOI:
10.1007/s13760-023-02269-z
No abstract available
Publication types
Letter
MeSH terms
1-Deoxynojirimycin
Humans
Myoclonic Epilepsies, Progressive*
Myoclonus* / drug therapy
Substances
miglustat
1-Deoxynojirimycin